HEMATOLOGIC AND LYMPHOCYTIC DISORDER
Clinical trials for HEMATOLOGIC AND LYMPHOCYTIC DISORDER explained in plain language.
Never miss a new study
Get alerted when new HEMATOLOGIC AND LYMPHOCYTIC DISORDER trials appear
Sign up with your email to follow new studies for HEMATOLOGIC AND LYMPHOCYTIC DISORDER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can a drug combo stop AML from coming back?
Disease control OngoingThis phase II trial tests whether a combination of two drugs, azacitidine and venetoclax, can help keep acute myeloid leukemia (AML) in remission after initial treatment. The study enrolls 50 adults whose AML is in first remission but who are not ready for a stem cell transplant.…
Matched conditions: HEMATOLOGIC AND LYMPHOCYTIC DISORDER
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New drug aims to stop transplant attack on the body
Disease control OngoingThis phase 2 trial tests whether the drug itacitinib, given with standard care, can prevent graft-versus-host disease (GVHD) in people who receive a donor stem cell transplant for blood cancers. GVHD happens when the donor cells attack the patient's body. The study includes 31 ad…
Matched conditions: HEMATOLOGIC AND LYMPHOCYTIC DISORDER
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Can a psoriasis drug stop transplant rejection?
Disease control OngoingThis phase II trial tests whether the drug ustekinumab (Stelara) can prevent acute graft-versus-host disease (GVHD) in 116 adults receiving stem cell transplants for blood cancers. GVHD occurs when donor immune cells attack the patient's body. Ustekinumab aims to calm this immune…
Matched conditions: HEMATOLOGIC AND LYMPHOCYTIC DISORDER
Phase: PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
Engineered immune cells aim to tame chronic GVHD
Disease control TerminatedThis early-phase study tests a new treatment called CD6-CAR Tregs for people with chronic graft-versus-host disease (cGVHD), a complication after a stem cell transplant. The treatment uses specially engineered immune cells from a donor to help control the immune attack on the pat…
Matched conditions: HEMATOLOGIC AND LYMPHOCYTIC DISORDER
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC